临床I期非小细胞肺癌接受5次立体定向体部放疗的局部控制与治疗日程无关
该多机构系列研究纳入2005至2016年245例临床I期非小细胞肺癌患者,比较5次立体定向体部放疗连续(QD)与非连续(QoD)日程的局部失败率和总生存。倾向匹配分析显示QD与局部失败无关(OR 0.48,95%CI 0.12-1.99,P=.5),中位总生存两组均为38.0个月(log-rank P=.7),QD未增加死亡风险(HR 1.08,95%CI 0.67-1.75,P=.75)。
要点
- QD与QoD日程的局部失败无关联(OR 0.48,95%CI 0.12-1.99,P=.5)。
- 中央型肿瘤与局部复发可能性增加独立相关(OR 5.2,95%CI 1.11-24.2,P=.04)。
- QD与QoD的中位总生存均为38.0个月(log-rank P=.7),QD未增加死亡风险(HR 1.08,95%CI 0.67-1.75,P=.75)。
核心结论
- 该分析显示,对于早期非小细胞肺癌,QD与QoD治疗日程与局部控制或总生存无关。
研究设计与样本
- 研究合并2家高容量机构的肺立体定向体部放疗数据库,识别接受5次立体定向体部放疗的孤立性I期非小细胞肺癌患者。
- 2005年至2016年共识别245例临床I期非小细胞肺癌患者接受5次立体定向体部放疗。
- QD治疗定义为7天内完成立体定向体部放疗,QoD治疗定义为超过7天完成治疗。
- 为控制2家机构间患者特征,进行了1:1倾向匹配分析。
- 采用多变量逻辑回归识别与局部失败独立相关的变量,采用Cox比例风险模型识别与死亡增加独立相关的变量。
主要发现
- 117例(47.8%)患者接受QD治疗,128例(52.2%)患者接受QoD治疗。
- 倾向匹配分析中,QD治疗与局部失败无关联(QD治疗的比值比[OR]为0.48;95%置信区间[CI] 0.12-1.99;P=.5)。
- 多变量逻辑回归中,中央型肿瘤与局部复发可能性增加独立相关(OR 5.2;95%CI 1.11-24.2;P=.04)。
- Kaplan-Meier分析显示QD与QoD治疗的中位总生存无差异(38.0 vs 38.0个月,log-rank P=.7)。
- QD治疗与死亡风险增加无关(风险比1.08;95%CI 0.67-1.75;P=.75)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical concern remains regarding the relationship between consecutive (QD) versus nonconsecutive (QoD) lung stereotactic body radiation therapy (SBRT) treatment schedules and outcomes for clinical stage I non-small cell lung cancer (NSCLC). We examined a multi-institutional series of patients receiving 5-fraction lung SBRT to compare the local failure rates and overall survival between patients receiving QD versus QoD treatment. METHODS AND MATERIALS: Lung SBRT databases from 2 high-volume institutions were combined, and patients receiving 5-fraction SBRT for a solitary stage I NSCLC were identified. QD treatment was defined as completing SBRT in ≤7 days, whereas QoD treatment was defined as completing treatment in >7 days. To control for patient characteristics between the 2 institutions, a 1:1 propensity-matched analysis was performed. Multivariable logistic regression was performed to identify variables independently associated with local failure, and Cox proportional hazards modeling to identify variables independently associated with increased mortality. RESULTS: From 2005 through 2016, 245 clinical stage I NSCLC patients receiving 5-fraction SBRT were identified. A total of 117 (47.8%) patients received QD treatment and 128 (52.2%) patients received QoD treatment. On propensity-matched analysis, no association was seen between QD treatment and local failure (odds ratio [OR] for QD treatment, 0.48; 95% confidence interval [CI], 0.12-1.99; P = .5). On multivariable logistic regression, central tumors were independently associated with increased likelihood of local recurrence (OR, 5.2; 95% CI, 1.11-24.2; P = .04). Kaplan-Meier analysis identified no difference in median overall survival between QD versus QoD treatments (38.0 vs 38.0 months, log-rank P = .7), respectively. QD treatment was not associated with an increased mortality hazard (hazard ratio, 1.08; 95% CI, 0.67-1.75; P = .75). CONCLUSIONS: This analysis demonstrated no association between QD versus QoD treatment scheduling and local control or overall survival for early-stage NSCLC.
引用
- Samson P, Rehman S, Juloori A, et al. Local control for clinical stage I non-small cell lung cancer treated with 5-fraction stereotactic body radiation therapy is not associated with treatment schedule. Pract Radiat Oncol. 2018. PMID: 29907514. doi:10.1016/j.prro.2018.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。